Biochemical and clinical characteristics of patients with primary aldosteronism: Single centre experience
- PMID: 33033458
- PMCID: PMC7526022
- DOI: 10.2478/jomb-2019-0035
Biochemical and clinical characteristics of patients with primary aldosteronism: Single centre experience
Abstract
Background: Primary aldosteronism (PA) is associated with increased prevalence of metabolic disorders (impaired glucose and lipid metabolism and insulin resistance), but also with more frequent cardiovascular, renal and central nervous system complications.
Methods: Biochemical and clinical parameters were retrospectively analysed for 40 patients with PA caused by aldosterone-producing adenoma (APA) and compared to the control groups of 40 patients with nonfunctioning adrenal adenoma (NFA) and essential hypertension (HT), and 20 patients with adrenal Cushing syndrome (CS) or subclinical CS (SCS).
Results: Systolic, diastolic and mean arterial blood pressures were significantly higher in the PA group (p=0.004; p=0.002; p=0.001, respectively) than in NFA+HT group. PA patients had longer hypertension history (p=0.001) than patients with hypercorticism and all had hypokalaemia. This group showed the smallest mean tumour diameter (p<0.001). The metabolic syndrome was significantly less common in the PA group (37.5% vs. 70% in CS+SCS and 65% in NFA+HT group; p=0.015), although there was no significant difference in any of the analysed metabolic parameters between groups. PA group was found to have the most patients with glucose intolerance (81.8%), although the difference was not significant. The mean BMI for all three groups was in the overweight range. Patients with PA had higher microalbuminuria and a higher tendency for cardiovascular, renal and cerebrovascular events, but the difference was not significant.
Conclusions: Our results support the importance of the early recognition of primary aldosteronism on the bases of clinical presentation, as well as an increased screening intensity.
Uvod: Primarni aldosteronizam (PA) je praćen povećanom prevalencom metaboličkih poremećaja, (oštećen glukozni i lipidni metabolizam i insulinska rezistencija), ali i češćim kardio vaskularnim, renalnim i komplikacijama centralnog nervnog sistema.
Metode: Analizirane su retrospektivno biohemijske i kliničke karakteristike 40 pacijenata sa PA zbog aldosteron-produkujućeg adenoma (APA) i upoređene sa kontrolnim grupama od 40 pacijenata sa afunkcionim adrenalnim adenomom (NFA) i esencijalnom hipertenzijom (HT), i 20 pacijenata sa adrenalnim Cushing-ovim sindromom (CS) ili subkliničkim CS (SCS).
Rezultati: Sistolni, dijastolni i srednji arterijski pritisci su bili značajno viši u grupi sa PA (p=0,004; p=0,002; p=0,001, redom) nego u grupi NFA+HT. PA pacijenti su imali dužu istoriju hipertenzije (p=0,001) nego pacijenti sa hiperkorticizmom i svi su imali hipokalemiju. Ova grupa je imala najmanji srednji prečnik tumora (p<0,001). Metabolički sindrom je bio značajno ređi u PA grupi (37,5% vs. 70% u CS+SCS i 65% u NFA+HT grupi; p=0,015), mada nije bilo značajne razlike u bilo kom analiziranom metaboličkom parametru među grupama. U PA grupi je nađen najveći procenat pacijenata sa glikoznom intolerancijom (81,8%), mada razlika nije bila značajna. Srednja vrednost BMI za sve tri grupe je bila u rangu prekomerne težine. Pacijenti sa PA su imali veći stepen mikroalbuminurije, veću tendencija ka javljanju kardiovaskularnih, renalnih i cerebrovaskularnih događaja, ali razlika nije bila značajna.
Zaključak: Naši rezultati podržavaju značaj ranog prepoznavanja primarnog aldosteronizma na osnovu kliničke prezentacije, ali i povećanog korišćenja skrininga.
Keywords: Cushing syndrome; adrenal tumour; biochemical parameters; clinical presentation; hypertension; primary aldosteronism.
2020 Nataša Vujačić, Ivan Paunović, Aleksandar Diklić, Vladan Živaljević, Nikola Slijepčević, Nevena Kalezić, Mirjana Stojković, Miloš Stojanović, Biljana Beleslin, Miloš Žarković, Jasmina Ćirić, published by CEON/CEES.
Conflict of interest statement
Conflict of Interest: The authors stated that they have no conflicts of interest regarding the publication of this article.
Similar articles
-
The role of biochemical tests and clinical symptoms in differential diagnosis of primary aldosteronism.Kardiol Pol. 2003 Jan;58(1):17-26. Kardiol Pol. 2003. PMID: 14502298
-
[Clinical features and outcomes of surgical versus conservative management in patients with subclinical Cushing's syndrome].Zhonghua Yi Xue Za Zhi. 2020 Sep 29;100(36):2834-2840. doi: 10.3760/cma.j.cn112137-20200213-00274. Zhonghua Yi Xue Za Zhi. 2020. PMID: 32988143 Chinese.
-
[Clinical characteristics and prognosis of primary aldosteronism associated with subclinical Cushing syndrome].Zhonghua Nei Ke Za Zhi. 2024 Apr 1;63(4):378-385. doi: 10.3760/cma.j.cn112138-20230830-00100. Zhonghua Nei Ke Za Zhi. 2024. PMID: 38561283 Chinese.
-
Primary aldosteronism: renaissance of a syndrome.Clin Endocrinol (Oxf). 2007 May;66(5):607-18. doi: 10.1111/j.1365-2265.2007.02775.x. Clin Endocrinol (Oxf). 2007. PMID: 17492946 Review.
-
Update in diagnosis and management of primary aldosteronism.Clin Chem Lab Med. 2018 Feb 23;56(3):360-372. doi: 10.1515/cclm-2017-0217. Clin Chem Lab Med. 2018. PMID: 28844072 Review.
Cited by
-
The differences of serum lipid profiles between primary aldosteronism and essential hypertension: a meta-analysis and systematic review.BMC Endocr Disord. 2022 Aug 31;22(1):217. doi: 10.1186/s12902-022-01135-y. BMC Endocr Disord. 2022. PMID: 36045354 Free PMC article.
-
Differences in Glycemic Abnormalities Between Primary Aldosteronism and Essential Hypertension: A Systematic Review and Meta-Analysis.Front Endocrinol (Lausanne). 2022 Mar 31;13:870047. doi: 10.3389/fendo.2022.870047. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35432215 Free PMC article.
References
-
- Stowasser M, Gordon R D, Gunasekera T G, Cowley D C, Ward G, Archibald C, Smithers M B. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens. 2003;21(11):2149. doi: 10.1097/00004872-200311000-00025. - DOI - PubMed
-
- Funder J W, Carey R M, Mantero F, Murad H M, Reincke M, Shibata H, Stowasser M, Young W F. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889. doi: 10.1210/jc.2015-4061. - DOI - PubMed
-
- Käyser S C, Dekkers T, Groenewoud H J, van der Wilt G J, Carel B J, van der Wel M C, Hermus A R, Lenders J W, Deinum J. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab. 2016;101(7):2826. doi: 10.1210/jc.2016-1472. - DOI - PubMed
-
- Heinrich D A, Adolf C, Rump L C, Quack I C, Quinkler M, Hahner S, Januszewicz A, Seufert J, Willenberg H S, Nirschl N, Sturm L, Beuschlein F, Reincke M. Primary aldosteronism: key characteristics at diagnosis: A trend toward milder forms. Eur J Endocrinol. 2018;178(6):605. doi: 10.1530/eje-17-0978. - DOI - PubMed
LinkOut - more resources
Full Text Sources